Department of Endocrinology, Diabetology and Metabolic Diseases (B.V., A.R.), University Hospital, Dijon, France.
University of Burgundy, INSERM (Institut national de la santé et de la recherche médicale) CTM (Centre de recherche Translationnelle en Médecine moléculaire) UMR1231, Dijon, France (B.V., L.D., A.R.).
Arterioscler Thromb Vasc Biol. 2024 Aug;44(8):1873-1883. doi: 10.1161/ATVBAHA.124.320774. Epub 2024 Jun 20.
Pathogenic variants in -encoding PLIN1 (perilipin-1) are responsible for an autosomal dominant form of familial partial lipodystrophy (FPL) associated with severe insulin resistance, hepatic steatosis, and important hypertriglyceridemia. This study aims to decipher the mechanisms of hypertriglyceridemia associated with -related FPL.
We performed an in vivo lipoprotein kinetic study in 6 affected patients compared with 13 healthy controls and 8 patients with type 2 diabetes. Glucose and lipid parameters, including plasma LPL (lipoprotein lipase) mass, were measured. mRNA and protein expression were evaluated in abdominal subcutaneous adipose tissue from patients with 5 -mutated FPL and 3 controls.
Patients with -mutated FPL presented with decreased fat mass, insulin resistance, and diabetes (glycated hemoglobin A1c, 6.68±0.70% versus 7.48±1.63% in patients with type 2 diabetes; mean±SD; =0.27). Their plasma triglycerides were higher (5.96±3.08 mmol/L) than in controls (0.76±0.27 mmol/L; <0.0001) and patients with type 2 diabetes (2.94±1.46 mmol/L, =0.006). Compared with controls, patients with -related FPL had a significant reduction of the indirect fractional catabolic rate of VLDL (very-low-density lipoprotein)-apoB100 toward IDL (intermediate-density lipoprotein)/LDL (low-density lipoprotein; 1.79±1.38 versus 5.34±2.45 pool/d; =0.003) and the indirect fractional catabolic rate of IDL-apoB100 toward LDL (2.14±1.44 versus 7.51±4.07 pool/d; =0.005). VLDL-apoB100 production was not different between patients with -related FPL and controls. Compared with patients with type 2 diabetes, patients with -related FPL also showed a significant reduction of the catabolism of both VLDL-apoB100 (=0.031) and IDL-apoB100 (=0.031). Plasma LPL mass was significantly lower in patients with -related FPL than in controls (21.03±10.08 versus 55.76±13.10 ng/mL; <0.0001), although the LPL protein expression in adipose tissue was similar. VLDL-apoB100 and IDL-apoB100 indirect fractional catabolic rates were negatively correlated with plasma triglycerides and positively correlated with LPL mass.
We show that hypertriglyceridemia associated with -related FPL results from a marked decrease in the catabolism of triglyceride-rich lipoproteins (VLDL and IDL). This could be due to a pronounced reduction in LPL availability, related to the decreased adipose tissue mass.
编码 PLIN1( perilipin-1)的基因突变与常染色体显性家族性部分脂肪营养不良(FPL)有关,这种疾病与严重的胰岛素抵抗、肝脂肪变性和显著的高三酰甘油血症有关。本研究旨在阐明与 FPL 相关的基因突变引起的高三酰甘油血症的机制。
我们对 6 名受影响的患者进行了体内脂蛋白动力学研究,并与 13 名健康对照者和 8 名 2 型糖尿病患者进行了比较。测量了血糖和脂质参数,包括血浆脂蛋白脂肪酶(LPL)质量。对 5 例 FPL 突变患者和 3 例对照者的腹部皮下脂肪组织中的 mRNA 和蛋白表达进行了评估。
FPL 突变患者的脂肪量减少、胰岛素抵抗和糖尿病(糖化血红蛋白 A1c,6.68±0.70%比 2 型糖尿病患者的 7.48±1.63%;=0.27)。他们的血浆三酰甘油水平高于对照组(5.96±3.08 mmol/L)(0.0001)和 2 型糖尿病患者(2.94±1.46 mmol/L,=0.006)。与对照组相比,FPL 相关患者极低密度脂蛋白(VLDL)-apoB100 的间接分解代谢率明显降低,向 IDL/LDL 的转化(VLDL-apoB100;1.79±1.38 对 5.34±2.45 池/d;=0.003)和 IDL-apoB100 向 LDL 的转化(2.14±1.44 对 7.51±4.07 池/d;=0.005)。FPL 相关患者的 VLDL-apoB100 生成率与对照组无差异。与 2 型糖尿病患者相比,FPL 相关患者的 VLDL-apoB100(=0.031)和 IDL-apoB100(=0.031)的分解代谢率也明显降低。FPL 相关患者的血浆 LPL 质量明显低于对照组(21.03±10.08 对 55.76±13.10 ng/mL;<0.0001),尽管脂肪组织中的 LPL 蛋白表达相似。VLDL-apoB100 和 IDL-apoB100 的间接分解代谢率与血浆三酰甘油呈负相关,与 LPL 质量呈正相关。
我们表明,FPL 相关的高三酰甘油血症是由于富含甘油三酯的脂蛋白(VLDL 和 IDL)的代谢明显减少所致。这可能是由于 LPL 可用性的显著降低,与脂肪组织质量的减少有关。